Navigation Links
Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Date:2/14/2012

CHATTANOOGA, Tenn., Feb. 14, 2012 /PRNewswire/ -- Glenveigh Medical  announced today that the U.S. Food and Drug Administration (FDA) has granted its request for orphan drug designation for a potential new therapy to treat severe preeclampsia and eclampsia. The compound, digoxin immune fab (ovine), is an existing biologic approved for use in cases of digoxin toxicity. Glenveigh, a nationally renowned life science company, has extensive clinical and in vitro evidence to support continued development of this late-stage opportunity. Preeclampsia occurs in 5-8% of pregnancies in the U.S., and these severe forms are leading causes of maternal and perinatal mortality globally.

"This is a tremendous milestone for our company," stated C. David Adair, M.D., Founder, Chairman, and Chief Scientific Officer of Glenveigh. "As a physician and scientist, I have personally seen the devastation these conditions have caused to both moms and babies.  Our program, which includes two successful Phase II studies, offers hope to patients that there will be a treatment for severe preeclampsia in the near future."

Preeclampsia is a condition in pregnant women that is characterized by high blood pressure and excess protein in the urine in the second and third trimesters of pregnancy. Severe preeclampsia and eclampsia represent the most advanced stages of the disease in which pregnant women can suffer from seizures and organ failure.

"In addition to our patents, orphan designation gives Glenveigh at least 7 years of marketing exclusivity," noted Rick Proctor, President and CEO. "We are delighted that the FDA granted orphan drug designation which gives innovators added incentives to pursue treatments for smaller patient populations."

Eleni Tsigas, Executive Director of the Preeclampsia Foundation, added, "Severe preeclampsia can be life-threatening to mother and baby.  Effective interventions for this serious disorder of pregnancy are lacking. We are thrilled that this designation can better enable further research and development that may lead to a potential therapy."

ABOUT GLENVEIGH MEDICAL | www.glenveigh.com  

Glenveigh Medical is a life science and technology based company focused on advancing the practice of obstetrics. Founded in 2004 by a maternal-fetal medicine specialist, Glenveigh prides itself on bringing innovative solutions to the obstetrics industry, relying upon its scientific and medical advisors to provide guidance on market opportunities that will significantly benefit patients in need. Glenveigh's marketed products include the following medical devices: ebb® (post partum hemorrhage), jetty® (vaginal repairs), and Beacon™ (wireless fetal monitor). Glenveigh is based in Chattanooga, Tennessee.


'/>"/>
SOURCE Glenveigh Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
2. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
3. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
4. Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
5. Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
6. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
7. CORD:USE Cord Blood Bank Featured Internationally on CNN en Espanol
8. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
9. Lilly Recognized as a Top Company for Executive Women
10. The Lanier Law Firms Dana Taschner Recognized Among Southern Californias Top Lawyers
11. nContacts Corporate Website Recognized as Best in Class Medical Site by Interactive Media Council - www.ncontactinc.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology:
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):